Glenmark Pharma Launches World’s First Nebulized Triple Therapy For COPD

Mumbai, November 25, 2025: Glenmark Pharmaceuticals Ltd, listed on NSE and BSE, has announced the launch of Nebzmart GFB Smartules and Glenmark Airz FB Smartules. This, according to the company, is the world’s first nebulized fixed-dose triple therapy for patients suffering from Chronic Obstructive Pulmonary Disease or COPD.

Share Market Snapshot

As of 13:40 IST, the share price of Glenmark Pharmaceuticals Ltd was trading at ₹1,878, up 1.93% from its previous close of ₹1,842.40. The share opened at ₹1,842 and traded between ₹1,893.60 and ₹1,837 so far. The market cap of the shares was 51,992.70 Cr, which was high by industry standards.

A New Milestone in Respiratory Treatment

The combination of Glycopyrronium Formoterol and Budesonide into one unit dose nebulized therapy provides a much easier way for those patients who have difficulty using MDIs and DPIs to get their medications. The new formulation is intended to prevent or alleviate airway obstruction, control inflammation, and enhance the patient’s lung capacity and function.

According to Glenmark, the new medication will provide the best option for patients with chronic obstructive pulmonary disease. It is best for those who need to take multiple medications but have difficulty coordinating the use of the devices used for delivery (e.g. inhalers).

Clinical Outcomes Indicate Strong Efficacy

The results of a clinical study conducted in India demonstrated the effectiveness of nebulized triple therapy by delivering rapid improvement in lung function and reduction of breathlessness. The treatment itself was found to be safe and well-tolerated by all subjects involved.

Leadership Outlook

The President and Business Head of India Formulations, Alok Malik, said, ‘This launch reaffirms Glenmark’s commitment to advance respiratory innovation through creating better therapies that are easy for patients to access and use. The Global Head of Clinical Development, Dr. Monika Tandon, mentions that this new treatment represents a tremendous step forward in managing COPD, with both great clinical performance and patient-friendly usage.

Glenmark Pharmaceuticals Ltd is a research-led global pharmaceutical organization operating across branded generics and OTC segments. Boasting 11 manufacturing facilities across four continents and commercial presence in over 80 countries, the company focuses mainly on respiratory dermatology and oncology therapeutics. Glenmark ranks among the leading global companies in R&D and pharmaceutical sales and continues to progress sustainability targets through its approved emission-reduction projects.

REF: https://nsearchives.nseindia.com/corporate/GLENMARK_25112025085912_PR_BSE_NSE_25112025.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations